IPH 2101

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
IPH 2101
DrugBank Accession Number
DB06049
Background

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • 1-7F9
  • Anti-KIR (1-7F9)
  • IPH 2101
  • IPH-2101
  • IPH2101
  • NN-1975

Pharmacology

Indication

Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with IPH 2101.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with IPH 2101.
AducanumabThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with IPH 2101.
AlirocumabThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when IPH 2101 is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when IPH 2101 is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5Q686XLG8L
CAS number
1000676-42-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentSmoldering Multiple Myeloma (SMM)1
1CompletedTreatmentAcute Myeloid Leukemia (AML)1
1CompletedTreatmentFirst or Second Relapse / Patients With Multiple Myeloma Experiencing a1
1CompletedTreatmentMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on November 18, 2007 18:29 / Updated on June 12, 2020 16:52